Viviscal is First Hair Growth Supplement to Present to Prestigious Hair Research Group

by Viviscal Hair Expert on May 17th, 2013

Scientists, clinicians and hair care product companies gathered to share their knowledge and exchange ideas regarding clinical hair research at the 7th World Congress for Hair Research in Edinburgh, Scotland, which was held from the 4th through the 6th of May in 2013. The conference is a haven for like-minded hair health professionals looking to improve upon existing hair growth options and eradicate scalp disease in addition to many forms of alopecia. The event welcomed hair research societies from Europe, North America, Japan, Korea, India and Australia; product demonstrations, research presentations and the sharing of new innovations in hair care research was encouraged.

Prominent Vancouver, BC, hair supplement manufacturer, RepliCel Life Sciences Inc., discussed the 12-month safety results of its product. Led by RepliCel’s chief scientific officer, Dr. Kevin McElwee, the presentation provided a breakdown of Phase I of the company’s clinical trials, which utilized RCH-01 as a possible combatant against androgenetic alopecia. Biologix Hair Inc., a patent-pending hair therapy system manufacturer based out of Ontario, Canada, exhibited its product to increase awareness of its efficacy. The company is currently seeking FDA approval of its Biologix Hair Therapy System™ for use within the United States.

Viviscal, containing an amino-rich marine complex formulated to promote the growth of existing hair for both men and women, made history in Edinburgh when it became the first dietary supplement to be welcomed by the World Congress for the treatment of thinning hair. Viviscal representative, Dr. Glynis Ablon, M.D., FAAD, offered up statistically significant findings from the company’s 2012 hair growth program, “Viviscal Double Blind Placebo Controlled Trial on Women 2012.” In a study of daily supplement doses given to women with perceived thinning of hair, overall hair thickness increased by 7.4 percent after six months, and hair shedding reduced by 18.3 percent after just three months. The double-blind, placebo-controlled study was conducted at multiple sites for a duration of six months.

T. Nakajima, EH. Wang, K. Matsushima, A. de Jong, T. Lovewell, SI. Jo and X. Wu were awarded poster prizes during the conference, while L. Poterlowicz and C. Clavel were recognized for putting on the best presentations. Lynn Petukhova, a research associate at Columbia University, has performed extensive research to define and establish the genetic basis of alopecia areata. Petukhova was awarded with the prestigious Jurgen Schweizer Award following the triennial conference.

These and other significant findings were discussed during the conference, allowing its participants to brainstorm better hair loss solutions in addition to devising possible solutions to the most common causes of hair and scalp problems that plague thousands of people globally. With the information presented during the 7th World Congress for Hair Research, national hair health association members are better equipped to manufacture products that could one day put an end to hair loss once and for all.